消息列表
| List of Messages
【恭賀】林君榮院長研究團隊開發之新藥獲美國FDA核准進入第一期臨床試驗
本院林君榮院長和中研院轉譯中心陳儀莊特聘研究員共同開發用於治療阿茲海默症及神經退化疾病之新藥獲美國FDA核准進行第一期臨床試驗。
阿茲海默症是老年社會中常見的神經退化疾病，目前只有少數臨床藥物可用於治療，也無法顯著改變病情進展。本研究團隊所開發的新藥（J4）是一種新的核苷轉運蛋白（ENT1）抑制劑，能改善腦部能量平衡，並在小鼠實驗中顯示出優異效果。J4的療效預期將比現有藥物更好並具備良好的安全性，期望能為阿茲海默症患者帶來更好的治療選擇，改善病情與生活品質。
The translational research team led by Dr. Chun-Jung Lin and Dr. Yijuang Chern has developed a novel drug for the treatment of Alzheimer's disease and other neurodegenerative disorders, which has been approved by the U.S. FDA for a Phase I clinical trial.
Alzheimer's disease is a prevalent neurodegenerative disorder in aging societies, with only a limited number of available drugs, none of which significantly alter disease progression. The new drug, J4, developed by Dr. Chern's team, is a novel inhibitor of the Equilibrative Nucleoside Transporter 1 (ENT1), designed to improve brain energy homeostasis. Preclinical studies have shown promising results, with J4 demonstrating strong efficacy and excellent safety. J4 is expected to offer superior therapeutic benefits compared to existing treatments, providing Alzheimer's patients with better treatment options and improved quality of life.
(Contact: Ms. Jean Wu, +886-2-27899034, jeanwenwu1202@gmail.com)
檔案下載：NTUDOP_NEWS_1130826.pdf
阿茲海默症是老年社會中常見的神經退化疾病，目前只有少數臨床藥物可用於治療，也無法顯著改變病情進展。本研究團隊所開發的新藥（J4）是一種新的核苷轉運蛋白（ENT1）抑制劑，能改善腦部能量平衡，並在小鼠實驗中顯示出優異效果。J4的療效預期將比現有藥物更好並具備良好的安全性，期望能為阿茲海默症患者帶來更好的治療選擇，改善病情與生活品質。
The translational research team led by Dr. Chun-Jung Lin and Dr. Yijuang Chern has developed a novel drug for the treatment of Alzheimer's disease and other neurodegenerative disorders, which has been approved by the U.S. FDA for a Phase I clinical trial.
Alzheimer's disease is a prevalent neurodegenerative disorder in aging societies, with only a limited number of available drugs, none of which significantly alter disease progression. The new drug, J4, developed by Dr. Chern's team, is a novel inhibitor of the Equilibrative Nucleoside Transporter 1 (ENT1), designed to improve brain energy homeostasis. Preclinical studies have shown promising results, with J4 demonstrating strong efficacy and excellent safety. J4 is expected to offer superior therapeutic benefits compared to existing treatments, providing Alzheimer's patients with better treatment options and improved quality of life.
(Contact: Ms. Jean Wu, +886-2-27899034, jeanwenwu1202@gmail.com)
檔案下載：NTUDOP_NEWS_1130826.pdf